Endogenous fibroblast growth factor 2 is cardioprotective in an in vivo, closed-chest, murine model of regional cardiac ischemia-reperfusion injury

Stacey House  
*Washington University School of Medicine in St. Louis*

Carla Weinheimer  
*Washington University School of Medicine in St. Louis*

Attila Kovacs  
*Washington University School of Medicine in St. Louis*

David Ornitz  
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [http://digitalcommons.wustl.edu/em_conf](http://digitalcommons.wustl.edu/em_conf)

Recommended Citation  
House, Stacey; Weinheimer, Carla; Kovacs, Attila; and Ornitz, David, "Endogenous fibroblast growth factor 2 is cardioprotective in an in vivo, closed-chest, murine model of regional cardiac ischemia-reperfusion injury" (2012). *Conference Abstracts and Posters*. Paper 16.  
[http://digitalcommons.wustl.edu/em_conf/16](http://digitalcommons.wustl.edu/em_conf/16)

This Presentation Paper is brought to you for free and open access by the Division of Emergency Medicine/Emergency Care Research Section at Digital Commons@Becker. It has been accepted for inclusion in Conference Abstracts and Posters by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Endogenous Fibroblast Growth Factor 2 is Cardioprotective in an In Vivo, Closed-Chest, Murine Model of Regional Cardiac Ischemia-Reperfusion Injury

Stacey House MD PhD, Carla Weinheimer MS, Attila Kovacs MD, and David Ornitz MD PhD

Washington University in St. Louis School of Medicine, St. Louis, Missouri

Fibroblast growth factor 2 (FGF2) has been shown to be cardioprotective in ex vivo and chronic ischemia models. Limited data is available on the ability of FGF2 to protect the heart from ischemia-reperfusion injury in vivo. We have utilized a clinically relevant, in vivo, closed-chest model of regional cardiac ischemia-reperfusion (IR) injury. Mice with a targeted ablation of the Fgf2 gene (Fgf2/-) and wildtype controls were subjected to 90 minutes of occlusion of the left anterior descending artery followed by reperfusion for 7 days. Fgf2/- mice do not show any baseline abnormalities in cardiac morphometry or function. When subjected to closed-chest, regional cardiac IR injury, Fgf2/- mice have significantly increased myocardial infarct size as measured by echocardiography compared to wildtype mice at both 1 day and 7 days post-IR injury (p<0.05). In addition, Fgf2/- mice show significantly worsened cardiac function at 1 day and 7 days post-IR injury (p<0.05). Scar length, detected by trichrome and picrosirius red staining, is significantly increased in Fgf2/- hearts (p<0.05). Myocyte cross-sectional area measurement shows an impaired cardiac hypertrophic response in the Fgf2/- hearts in the peri-infarct area (p<0.05) but not in remote myocardium. Fgf2/- mice have normal vessel density compared to wildtype controls in the non-injured state, but after cardiac IR injury, Fgf2/- hearts showed significantly decreased vessel density (both capillaries and smooth muscle actin containing vessels) in the peri-infarct area compared to wildtype controls (p<0.05), suggesting a defect in vascular remodeling in the Fgf2/- mice after IR injury. Endogenous FGF2 improves cardiac function, reduces myocardial infarct size, and mediates cardiomyocyte hypertrophy and vascular remodeling after cardiac IR injury. These data show the cardioprotective potential of endogenous FGF2 in a clinically-relevant, in vivo, closed-chest, regional cardiac ischemia-reperfusion model which mimics acute myocardial infarction.